ISSAR Pharma

Psoriasis patients undergoing biologic/other systemic therapies may experience mild SARS-CoV-2 infection

Psoriasis patients undergoing biologic/other systemic therapies may experience mild SARS-CoV-2 infection

Psoriasis patients undergoing biologic/other systemic therapies may experience mild SARS-CoV-2 infection

A recent study published in the ‘Medicina’ Journal by the Multidisciplinary Digital Publishing Institute (MDPI), indicated that patients with psoriasis, administered with systemic therapy or other biologic treatments may experience a mild covid-19 infection and temporary exacerbation of psoriasis skin lesions.

Biological drugs play a key role in effective management of psoriasis. Severe psoriasis requires biologics to control disease progression through immunosuppression. However, it is unclear whether this immunosuppression increases the risk of SARS-CoV-2 infection. Therefore, this study aimed to assess the impact of biologic drugs in psoriasis patients, in relation to the SARS-CoV-2 infection.

The study was a one year observational study, which included 58 patients diagnosed with psoriasis and qualified for treatment with biological treatment. Another group of 68 patients received a different systemic treatment.

Patients were monitored each month for psoriasis disease activity and SARS-CoV-2 infection. Dermatological examination for psoriasis and symptomatic evaluation for covid-19 infection were carried out. Cases of covid-19 were confirmed through positive Real Time Polymerase Chain Reaction (RT-PCR) tests.

The results of the study showed that 14% of the psoriasis patients on biological therapy tested positive for the covid-19 infection, although none of them required hospitalization. It was also noted that 75% of patients receiving biological treatment, had experienced exacerbation of psoriasis, with similar results observed in the control group.

Thus, the results of the study suggested that psoriasis patients undergoing biological treatment or other systemic treatments may experience a mild covid-19 infection along with exacerbation of psoriasis symptoms.

Source: Mroz M, Mućka S, Miodońska M, Ziolkowska D, Hadas E, Bożek A. Influence of SARS-CoV-2 Virus Infection on the Course of Psoriasis during Treatment with Biological Drugs. Medicina (B Aires). (2021); 57(9):881.

Source link: https://www.mdpi.com/1648-9144/57/9/881